XORTX Therapeutics (XRTX) Long-Term Deferred Tax (2025 - 2026)

XORTX Therapeutics' (XRTX) quarterly Long-Term Deferred Tax came in at $356715.0 in Q1 2026, up 21.41% on a QoQ basis from $293803.0 in Q4 2025.

XORTX Therapeutics (XRTX) Long-Term Deferred Tax (2025 - 2026) Analysis & Trends

XORTX Therapeutics (XRTX) has 2 years of Long-Term Deferred Tax data on file, last reported at $356715.0 in Q1 2026.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $356715.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $356715.0 (changed N/A YoY) and the FY2025 annual result came in at $293803.0, changed N/A from the prior year.
Long-Term Deferred Tax climbed to $356715.0 in Q1 2026, from $293803.0 in the prior quarter.
In the past five years, Long-Term Deferred Tax ranged from a high of $356715.0 in Q1 2026 to a low of $293803.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.09 Bn	131.23 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.66 Bn	77.66 Bn	3.93 Bn
3	Argenx Se	64.86 Bn	59.67 Bn	1.37 Bn
4	Moderna	58.07 Bn	52.93 Bn	52.00 Mn
5	BeOne Medicines	41.87 Bn	36.77 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.45 Bn	28.15 Bn	992.69 Mn
7	BioNTech SE	27.90 Bn	9.51 Bn	668.28 Mn
8	Insmed	27.40 Bn	26.24 Bn	358.27 Mn
9	Royalty Pharma	27.28 Bn	26.45 Bn	-
10	XORTX Therapeutics	2.84 Mn	2.84 Mn	-

Download Data

Date	Value
Mar 31, 2026	356,715.00
Dec 31, 2025	293,803.00